Gene Therapy Holds Out Hope for Diabetics
NetworkNewsWire Editorial Coverage: Since its first successful use nearly 30 years ago, gene therapy has grown into an important if experimental part of the medical sector. Now it is taking off in a big way, offering treatment for chronic ailments such as diabetes and other conditions. PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (PRVCF Profile) is at the forefront of this segment of healthcare, seeking preventive gene treatments to tackle Type 2 diabetes. MannKind Corp. (NASDAQ: MNKD) is offering other innovations for diabetics, with the first inhalation-based drug for managing insulin levels, and Danish multinational Novo Nordisk (NYSE: NVO)…







